http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#Head http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#provenance http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#pubinfo http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion http://purl.obolibrary.org/obo/DOID_2957 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2957 http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01201 http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association http://www.w3.org/2000/01/rdf-schema#label priftin is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis tb caused by mycobacterium tuberculosis 1 1 priftin is indicated for the treatment of latent tuberculosis infection ltbi caused by m tuberculosis 1 2 see limitations of use 1 1 1 2 priftin a r mycobacterium tuberculosis see dosage and administration 2 1 clinical studies 14 1 limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid inh in hiv infected patients with active pulmonary tuberculosis because of a higher rate of failure and or relapse with rifampin rif resistant organisms see warnings and precautions 5 3 clinical studies 14 1 priftin has not been studied as part of the initial phase treatment regimen in hiv infected patients with active pulmonary tuberculosis priftin is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by mycobacterium tuberculosis see clinical studies 14 2 limitations of use active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection priftin must always be used in combination with isoniazid as a 12 week once weekly regimen for the treatment of latent tuberculosis infection see dosage and administration 2 2 clinical studies 14 2 priftin in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycin resistant or isoniazid resistant m tuberculosis http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01201 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#provenance http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#pubinfo http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig http://purl.org/nanopub/x/hasSignature VTVI7yu9OWKoJQDQjcgQY8jJFcf4O7t7U6uCiU03UcoawzLSSwmO08DqI1VpNfBErzbywalgMG9oYs0USK+Qlw2a8ixon91qPELHb0kWivG0Z3wc8JFt8DFr7Idze/yRYZvTHJ57y3swmp9rxl46VR8NdkhhpggUDtuy2mT6k4Q= http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://purl.org/dc/terms/created 2021-06-15T18:15:57.113+02:00 http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs